Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (226)	2/16/2000 12:50:00 PM
From: jeffbas	Respond to of 438

Today's move is probably in response to some investor forum they are at today, that I saw reported somewhere. While I thought the idea of the stock being held back amusing, it can be turned around a bit differently to my way of thinking. The stock evidently is on enough radar screens now that the price would definitely reflect positive scientific news, like an IND on aaATIII or positive results on the vaccine trials. I would not have been so sure 6 months ago.

To: Pseudo Biologist who wrote (226)	2/16/2000 12:51:00 PM
From: scaram(o)uche	Respond to of 438

Chuckle. I lead the world in money left on table in this rally. A classical perspective of the sector is the last thing one wanted. Obligatory relevance....... Nat Med 2000 Feb;6(2):196-9 Maspin is an angiogenesis inhibitor. Zhang M, Volpert O, Shi YH, Bouck N Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA. [Medline record in process] Maspin, a unique member of the serpin family, is a secreted protein encoded by a class II tumor suppressor gene whose downregulation is associated with the development of breast and prostate cancers. Overexpression of maspin in breast tumor cells limits their growth and metastases in vivo. In this report we demonstrate that maspin is an effective inhibitor of angiogenesis. In vitro, it acted directly on cultured endothelial cells to stop their migration towards basic fibroblast growth factor and vascular endothelial growth factor and to limit mitogenesis and tube formation. In vivo, it blocked neovascularization in the rat cornea pocket model. Maspin derivatives mutated in the serpin reactive site lost their ability to inhibit the migration of fibroblasts, keratinocytes, and breast cancer cells but were still able to block angiogenesis in vitro and in vivo. When maspin was delivered locally to human prostate tumor cells in a xenograft mouse model, it blocked tumor growth and dramatically reduced the density of tumor-associated microvessels. These data suggest that the tumor suppressor activity of maspin may depend in large part on its ability to inhibit angiogenesis and raise the possibility that maspin and similar serpins may be excellent leads for the development of drugs that modulate angiogenesis.